Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Receivables: 2022-2024

Historic Change in Receivables for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Dec 2024 value amounting to $47.3 million.

  • Arcutis Biotherapeutics' Change in Receivables fell 49.25% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 42.13%. This contributed to the annual value of $47.3 million for FY2024, which is 172.40% up from last year.
  • Arcutis Biotherapeutics' Change in Receivables amounted to $47.3 million in FY2024, which was up 172.40% from $17.3 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Change in Receivables registered a high of $47.3 million during FY2024, and its lowest value of $8.5 million during FY2022.
  • In the last 3 years, Arcutis Biotherapeutics' Change in Receivables had a median value of $17.3 million in 2023 and averaged $24.4 million.
  • Data for Arcutis Biotherapeutics' Change in Receivables shows a peak YoY spiked of 172.40% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Arcutis Biotherapeutics' Change in Receivables stood at $8.5 million in 2022, then soared by 105.12% to $17.3 million in 2023, then skyrocketed by 172.40% to $47.3 million in 2024.